PL1682177T3 - Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej - Google Patents
Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowejInfo
- Publication number
- PL1682177T3 PL1682177T3 PL04810417T PL04810417T PL1682177T3 PL 1682177 T3 PL1682177 T3 PL 1682177T3 PL 04810417 T PL04810417 T PL 04810417T PL 04810417 T PL04810417 T PL 04810417T PL 1682177 T3 PL1682177 T3 PL 1682177T3
- Authority
- PL
- Poland
- Prior art keywords
- antigen
- antibody
- binding fragment
- antagonist anti
- antagonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 title 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 title 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 108010029697 CD40 Ligand Proteins 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 2
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010063916 CD40 Antigens Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000004654 survival pathway Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51733703P | 2003-11-04 | 2003-11-04 | |
| US52557903P | 2003-11-26 | 2003-11-26 | |
| US56571004P | 2004-04-27 | 2004-04-27 | |
| US61179404P | 2004-09-21 | 2004-09-21 | |
| EP04810417A EP1682177B8 (en) | 2003-11-04 | 2004-11-04 | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| PCT/US2004/036954 WO2005044304A2 (en) | 2003-11-04 | 2004-11-04 | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1682177T3 true PL1682177T3 (pl) | 2011-03-31 |
Family
ID=34577850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04810417T PL1682177T3 (pl) | 2003-11-04 | 2004-11-04 | Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070110754A1 (pl) |
| EP (2) | EP2243491A1 (pl) |
| JP (2) | JP4765037B2 (pl) |
| KR (1) | KR20070028295A (pl) |
| CN (1) | CN1929862B (pl) |
| AT (1) | ATE474598T1 (pl) |
| AU (1) | AU2004287480B2 (pl) |
| CA (1) | CA2544364A1 (pl) |
| CY (1) | CY1110836T1 (pl) |
| DE (1) | DE602004028270D1 (pl) |
| DK (1) | DK1682177T3 (pl) |
| HK (1) | HK1095269A1 (pl) |
| IL (1) | IL175393A0 (pl) |
| PL (1) | PL1682177T3 (pl) |
| PT (1) | PT1682177E (pl) |
| SI (1) | SI1682177T1 (pl) |
| WO (1) | WO2005044304A2 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2149585B1 (en) * | 2003-11-04 | 2013-08-14 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonistic anti-CD40 monoclonal antibodies |
| SI1680141T1 (sl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| ATE474599T1 (de) * | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom |
| CA2544368C (en) * | 2003-11-04 | 2014-04-01 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| US20050281815A1 (en) * | 2004-02-26 | 2005-12-22 | Dani Eshel | CD40 splice variants and their uses |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| CA2627891A1 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
| CN101325970B (zh) * | 2005-11-01 | 2013-08-14 | 诺华有限公司 | 抗cd40抗体的应用 |
| CN100503827C (zh) * | 2006-03-16 | 2009-06-24 | 复旦大学 | 一种乙型肝炎病毒疫苗增效蛋白及其基因 |
| JP5290152B2 (ja) | 2006-04-21 | 2013-09-18 | ノバルティス アーゲー | 拮抗剤抗ｃｄ４０抗体薬学的組成物 |
| CA2704499C (en) | 2007-11-07 | 2020-03-10 | Genentech, Inc. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
| US9617600B2 (en) | 2009-04-18 | 2017-04-11 | Genentech, Inc. | Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| WO2012125569A2 (en) | 2011-03-11 | 2012-09-20 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| JP2016011258A (ja) * | 2012-10-26 | 2016-01-21 | 株式会社ペルセウスプロテオミクス | 抗ヒトｃｄ４０モノクローナル抗体及びその利用 |
| CN116063481A (zh) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
| JP7038064B2 (ja) | 2016-04-18 | 2022-03-17 | セルデックス セラピューティクス インコーポレイテッド | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
| JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗ｐｄ－ｌ１抗体 |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| EP0751781B1 (en) | 1993-12-23 | 2004-05-26 | Immunex Corporation | Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders |
| WO1995023512A1 (en) | 1994-03-03 | 1995-09-08 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
| JP3919235B2 (ja) | 1997-06-13 | 2007-05-23 | ジェネンテク，インコーポレイテッド | 抗体製剤 |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US7288252B2 (en) | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2544368C (en) * | 2003-11-04 | 2014-04-01 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| ATE474599T1 (de) * | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom |
| SI1680141T1 (sl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| JP6039343B2 (ja) | 2012-10-04 | 2016-12-07 | キヤノン株式会社 | 電子機器、電子機器の制御方法、プログラム、記憶媒体 |
-
2004
- 2004-11-04 AU AU2004287480A patent/AU2004287480B2/en not_active Ceased
- 2004-11-04 PT PT04810417T patent/PT1682177E/pt unknown
- 2004-11-04 SI SI200431527T patent/SI1682177T1/sl unknown
- 2004-11-04 JP JP2006538510A patent/JP4765037B2/ja not_active Expired - Fee Related
- 2004-11-04 DK DK04810417.8T patent/DK1682177T3/da active
- 2004-11-04 WO PCT/US2004/036954 patent/WO2005044304A2/en active Application Filing
- 2004-11-04 CA CA002544364A patent/CA2544364A1/en not_active Abandoned
- 2004-11-04 KR KR1020067010901A patent/KR20070028295A/ko active IP Right Grant
- 2004-11-04 PL PL04810417T patent/PL1682177T3/pl unknown
- 2004-11-04 US US10/577,642 patent/US20070110754A1/en not_active Abandoned
- 2004-11-04 CN CN2004800397684A patent/CN1929862B/zh not_active Expired - Fee Related
- 2004-11-04 EP EP10007491A patent/EP2243491A1/en not_active Withdrawn
- 2004-11-04 DE DE602004028270T patent/DE602004028270D1/de active Active
- 2004-11-04 AT AT04810417T patent/ATE474598T1/de active
- 2004-11-04 EP EP04810417A patent/EP1682177B8/en not_active Not-in-force
-
2006
- 2006-05-02 IL IL175393A patent/IL175393A0/en unknown
-
2007
- 2007-01-25 HK HK07100894.0A patent/HK1095269A1/xx not_active IP Right Cessation
-
2010
- 2010-10-18 CY CY20101100928T patent/CY1110836T1/el unknown
-
2011
- 2011-01-17 JP JP2011007386A patent/JP2011116760A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005044304A2 (en) | 2005-05-19 |
| PT1682177E (pt) | 2010-11-29 |
| AU2004287480A1 (en) | 2005-05-19 |
| EP1682177B8 (en) | 2010-09-01 |
| CY1110836T1 (el) | 2015-06-10 |
| IL175393A0 (en) | 2006-09-05 |
| DK1682177T3 (da) | 2010-11-01 |
| CN1929862B (zh) | 2012-02-15 |
| KR20070028295A (ko) | 2007-03-12 |
| US20070110754A1 (en) | 2007-05-17 |
| DE602004028270D1 (de) | 2010-09-02 |
| WO2005044304A3 (en) | 2005-08-25 |
| EP1682177A2 (en) | 2006-07-26 |
| JP2007510664A (ja) | 2007-04-26 |
| EP1682177B1 (en) | 2010-07-21 |
| ATE474598T1 (de) | 2010-08-15 |
| EP2243491A1 (en) | 2010-10-27 |
| JP4765037B2 (ja) | 2011-09-07 |
| CA2544364A1 (en) | 2005-05-19 |
| SI1682177T1 (sl) | 2010-12-31 |
| AU2004287480B2 (en) | 2011-09-15 |
| JP2011116760A (ja) | 2011-06-16 |
| CN1929862A (zh) | 2007-03-14 |
| HK1095269A1 (en) | 2007-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL175393A0 (en) | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia | |
| WO2005044306A3 (en) | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection | |
| CY1111011T1 (el) | Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| CY1110874T1 (el) | Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας | |
| WO2007053661A3 (en) | Uses of anti-cd40 antibodies | |
| ATE541860T1 (de) | Humane antikörper gegen cd40 zur therapie von b- zell tumoren | |
| PL375041A1 (pl) | Ludzkie neutralizujące przeciwciała anty-OPGL, będące selektywnymi inhibitorami ścieżki OPGL | |
| JP2009518441A5 (pl) | ||
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| TW200637574A (en) | Treatment method | |
| RU2012136817A (ru) | СПОСОБЫ ЛЕЧЕНИЯ ДИАБЕТА АНТАГОНИСТАМИ Dll4 | |
| CY1114654T1 (el) | Anti-cd40 μονοκλωνικα αντισωματα ανταγωνιστες και μεθοδοι για την χρηση αυτων | |
| RU2008127884A (ru) | Способы применения cd40-связывающих веществ |